Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia

Marvin M. van Luijn, Willemijn van den Ancker, S. Marieke van Ham, Arjan A. van de Loosdrecht

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)


The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells
Original languageEnglish
Article numbere941737
Pages (from-to)e941737
Issue number12
Publication statusPublished - Dec 2014

Cite this